AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $97.7M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$97.7M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 5 added, 2 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- 6 awardsAwards on record
Key stats
Fundamentals Sep 30- Open
- $179.90
- 52-wk high
- $190.76
- High
- $190.76
- 52-wk low
- $23.30
- Low
- $179.73
- Prev close
- $186.13
- Mkt cap
- $12.34B
- Volume
- 3.68M
- Beta
- 2.22
- P/S
- 28.6x
- P/B
- 23.6x
- Profit margin
- -31.7%
- Op margin
- -30.6%
- ROE
- -29.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about TWST filings
Are insiders buying or selling Twist Bioscience Corp (TWST) stock?
Net selling: insiders sold $97.7M and bought $0 of TWST stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $92.9M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Leproust, Emily M. (Chief Executive Officer), who sold $82.2M. The latest filing was on Sep 25, 2026.
Which members of Congress have traded TWST recently?
None. No member of Congress disclosed a TWST trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this TWST smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position, insiders have been net selling, and 1 fin-fluencer is discussing it.
What funds are doing
Buys/Adds (3)
- DS
D.E. Shaw
$119.8M
added
- AL
Alger
$52.9M
added
- BO
Bank of America
$67.2M
added
What insiders are doing
How top traders are positioned
No tracked top-trader positions in TWST right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 12.0% below what analysts expected.
Earnings per share
-$0.50 expected
Reports Nov 13, 2026, in 43 days
Estimates as of Sep 30, 2026
EPS expected
-$0.04 to -$0.02
Revenue expected
10 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $99.0M | $103.7M | $110.7M | $118.4M |
| Cost of what it sold | $48.2M | $49.7M | $53.6M | $55.9M |
| Gross profit | $50.8M | $54.0M | $57.1M | $62.5M |
| What it spent | ||||
| Research and development | $17.0M | $17.1M | $19.7M | $18.0M |
| Sales and admin | $56.8M | $69.9M | $76.1M | $80.7M |
| Other operating costs | $7.0M | — | — | — |
| Total operating expenses | $80.8M | $86.9M | $95.8M | $98.7M |
| What was left | ||||
| Operating profit | -$29.9M | -$32.9M | -$38.7M | -$36.3M |
| Profit before tax | -$26.9M | -$30.3M | -$44.0M | -$34.7M |
| Tax | $256.0K | $253.0K | $43.0K | -$311.0K |
| Net profit | -$27.1M | -$30.5M | -$44.0M | -$35.1M |
| EBITDA | -$20.9M | -$26.7M | -$32.2M | -$28.0M |
Technicals
Price structure
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bullish
Twist Bioscience CEO Emily Leproust sells $279,183 in stock
NeutralSep 27Form 4 Twist Bioscience Corp For: 27 September By Investing.com
NeutralSep 27Under a June trading plan, Twist Bioscience (TWST) CEO Emily M. Leproust sold 5,203 shares in 10 transactions.
Leans bearishSep 25Twist Bioscience Stock Hits New High, Then Retreats: What's Happening?
NeutralSep 25Twist Bioscience Corporation Stock Analysis: Bullish Momentum Meets Overbought Risks
Leans bullishSep 25Twist Bioscience Stock Jumped 16% Thursday. Leerink Says Anthropic Made It Happen.
BullishSep 25Twist Bioscience stock hits 52-week high at 170.69 USD
Leans bullishSep 25A proposed share sale valued at $922,906 names Emily M. Leproust as the Twist Bioscience (TWST) account holder.
NeutralSep 24
Macro
10 macro signals shaping TWST right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results